白色脂肪组织,一种新型的抗风湿标:从其分泌能力和基于脂肪切除的治疗方法中获得线索
Peng Ye1,2, Qi-Hai Wang3, Wen-Ye Kong1,2
1Xin'an Medicine Research Center, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.
British journal of pharmacology
|April 22, 2024
概括
白色脂肪组织 (WAT) 功能障碍通过增加炎症分泌物,导致类风湿性关节炎 (RA). 准异常的WAT信号,特别是抑制PPARγ的肝素,可能会降低RA的严重程度.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 类风湿病学 类风湿病学
背景情况:
- 白色脂肪组织 (WAT) 在类风湿性关节炎 (RA) 发病过程中发挥作用.
- 调查WAT作为RA的潜在治疗点至关重要.
研究的目的:
- 探索WAT在类风湿性关节炎 (RA) 中的作用.
- 确定将WAT功能障碍与RA进展联系起来的分子机制.
主要方法:
- 在健康和辅助剂诱导关节炎 (AIA) 鼠标模型中对WAT进行比较分析.
- 在体外研究中使用了前脂肪细胞和THP-1单细胞.
- 蛋白质组分析 (UPLC/MS2) 用于识别差异表达蛋白质.
- PPARγ调制 (siRNA和激动剂) 和肝激素治疗.
主要成果:
- 在AIA大鼠中,WAT的含量较小,而叶黄素,eNAMPT,MCP-1,TNF-α和IL-6的分泌量增加.
- RA 患者的血清在前脂肪细胞中诱导了类似的炎症变化.
- 在AIA大鼠中,脂肪切除改善了免疫异常和关节炎.
- 肝素PON1,IGFBP4和GPIHBP1在RA血液中升高,并促进炎症.
- GPIHBP1抑制了PPARγ,损害了前脂肪细胞分化,并促进了炎症.
结论:
- 肝激素通过通过PPARγ抑制促进前脂肪细胞的炎症分泌物加剧RA.
- 针对异常的WAT分泌和已识别的信号通路,为RA提供了潜在的治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...


